Henry Gosebruch

ANI Pharmaceuticals, Inc., a diversified biopharmaceutical company, has appointed Henry Gosebruch to its Board of Directors. Gosebruch brings more than 30 years of experience in corporate strategy, business development, mergers and acquisitions, and finance across the biopharmaceutical sector.

Gosebruch has served as Chief Executive Officer of Lakefront Biotherapeutics NV, formerly Galapagos NV, since May 2025 and is also a member of its Board of Directors. Previously, from July 2023 to February 2025, he served as President and Chief Executive Officer of Neumora Therapeutics, a publicly traded neuroscience company.

Before joining Neumora, Gosebruch spent eight years at AbbVie, serving as Executive Vice President and Chief Strategy Officer from 2015 to 2023. During his tenure, he established and led AbbVie’s Corporate Strategy Office, overseeing corporate strategy, competitive intelligence, business development and mergers and acquisitions, search and evaluation, alliance management, and AbbVie Ventures.

Under his leadership, the group completed more than 100 transactions and investments, including AbbVie’s acquisition of Allergan. Earlier in his career, Gosebruch spent more than 20 years at J.P. Morgan, where he most recently served as Co-Head of North American M&A.

In addition to his corporate leadership experience, Gosebruch serves on the Advisory Board of the University of Pennsylvania Life Sciences & Management Program. He earned a B.S. in Economics from the Wharton School at the University of Pennsylvania and is a certified public accountant.

ANI Pharmaceuticals also announced that Muthusamy (Samy) Shanmugam has resigned from the Board of Directors. Shanmugam will continue in his executive roles as Head of Research and Development and Chief Operating Officer of New Jersey Operations.